Join our daily newsletter At The Bell to receive exclusive market insights
4DMedical (ASX:4DX) has inked a deal with the University of Chicago Medicine in the United States. The partnership will see UChicago Medicine embed 4DMedical’s advanced lung imaging technology into their clinical treatment processes.
The rollout of 4DMedical’s imaging products is expected to boost precision in diagnosing and managing lung conditions, consolidating UChicago Medicine’s standing as an early adopter in pulmonary care innovation.
UChicago Medicine has an excellent reputation for delivering best-in-class treatment for complex lung diseases.
“Our medical centre has seen firsthand the benefits of 4DMedical’s technology,” Dr. Kyle Hogarth, Professor of Medicine at UChicago Medicine, said.
“With the addition of CT LVAS and other products, we believe we have taken the next step in maximizing the information that can be obtained from a chest CT.”
4DMedical is also broadening its recent deal with the University of California San Diego (UCSD Health).
Dr. Jonathon Chung from UCSD Health underscored the importance of 4DMedical’s algorithms for both diagnostic and population-wide imaging studies.
4DMedical founder Andreas Fouras said: “Our win with UChicago Medicine signifies another critical step in our US expansion. This contract demonstrates the demand for our comprehensive portfolio.”
4D Medical has been trading at 48 cents.
Join the discussion: See what HotCopper users are saying about 4D Medical and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
